351 related articles for article (PubMed ID: 17553682)
1. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
Srivani P; Srinivas E; Raghu R; Sastry GN
J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
[TBL] [Abstract][Full Text] [Related]
3. Understanding the structure-activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses.
Yang GF; Lu HT; Xiong Y; Zhan CG
Bioorg Med Chem; 2006 Mar; 14(5):1462-73. PubMed ID: 16263288
[TBL] [Abstract][Full Text] [Related]
4. Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule.
Bunnage ME; Mathias JP; Wood A; Miller D; Street SD
Bioorg Med Chem Lett; 2008 Dec; 18(23):6033-6. PubMed ID: 18951784
[TBL] [Abstract][Full Text] [Related]
5. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and phosphodiesterase 5 inhibitory activity of new sildenafil analogues containing a phosphonate group in the 5(')-sulfonamide moiety of phenyl ring.
Kim DK; Young Lee J; Park HJ; Minh Thai K
Bioorg Med Chem Lett; 2004 May; 14(9):2099-103. PubMed ID: 15080987
[TBL] [Abstract][Full Text] [Related]
7. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
Corbin JD; Beasley A; Blount MA; Francis SH
Neurochem Int; 2004 Nov; 45(6):859-63. PubMed ID: 15312980
[TBL] [Abstract][Full Text] [Related]
8. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
De Young L; Yu D; Freeman D; Brock GB
Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
[TBL] [Abstract][Full Text] [Related]
9. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
10. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
[TBL] [Abstract][Full Text] [Related]
11. Changed phosphodiesterase selectivity and enhanced in vitro efficacy by selective deuteration of sildenafil.
Schneider F; Mattern-Dogru E; Hillgenberg M; Alken RG
Arzneimittelforschung; 2007; 57(6):293-8. PubMed ID: 17688073
[TBL] [Abstract][Full Text] [Related]
12. In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.
Antunes JE; Freitas MP; da Cunha EF; Ramalho TC; Rittner R
Bioorg Med Chem; 2008 Aug; 16(16):7599-606. PubMed ID: 18656371
[TBL] [Abstract][Full Text] [Related]
13. Should phosphodiesterase 5 selective inhibitors be used for uterine relaxation?
Méhats C; Schmitz T; Breuiller-Fouché M; Leroy MJ; Cabrol D
Am J Obstet Gynecol; 2006 Jul; 195(1):184-5. PubMed ID: 16813753
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and pharmacological evaluations of sildenafil analogues for treatment of erectile dysfunction.
Flores Toque HA; Priviero FB; Teixeira CE; Perissutti E; Fiorino F; Severino B; Frecentese F; Lorenzetti R; Baracat JS; Santagada V; Caliendo G; Antunes E; De Nucci G
J Med Chem; 2008 May; 51(9):2807-15. PubMed ID: 18393409
[TBL] [Abstract][Full Text] [Related]
15. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
[TBL] [Abstract][Full Text] [Related]
17. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
18. Sildenafil (Viagra) evokes retinal arteriolar dilation: dual pathways via NOS activation and phosphodiesterase inhibition.
Yuan Z; Hein TW; Rosa RH; Kuo L
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):720-5. PubMed ID: 18235020
[TBL] [Abstract][Full Text] [Related]
19. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Rotella DP; Sun Z; Zhu Y; Krupinski J; Pongrac R; Seliger L; Normandin D; Macor JE
J Med Chem; 2000 Apr; 43(7):1257-63. PubMed ID: 10753463
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]